Kellier N, Krohn K, Gilsenan AW, Harris DH, Andrews EB, Massica D. Forteo voluntary patient registry: 3-Year progress on a prospective osteosarcoma surveillance study. Poster presented at the American Society for Bone and Mineral Research Annual Meeting; October 6, 2013.
Gilsenan AW, Midkiff KD, Andrews EB, Von Scheele BG, Masica D, Ceberg J. Multinational collaboration: a long-term surveillance program for osteosarcoma and potential exposure to teriparatide. Presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.
Midkiff KD, Von Scheele BG, Gilsenan AW, Ceberg J, Alvegård T. Progress update for the postmarketing adult osteosarcoma surveillance study in five Nordic countries. Poster presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective study of plasma-derived factor VIII/vWF in immune tolerance induction therapy: the SPIRIT registry. Poster presented at the Annual Meeting of the National Hemophilia Foundation; October 2013.
Harris DH, Midkiff K, Gilsenan A, Kellier N, Masica D, Andrews E. Eight-year results from the US osteosarcoma surveillance study. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal.
Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Kellier N, Masica D. Approaches to long-term surveillance for rare cancer events. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2013. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2013 Aug; 22(Suppl 1):218-9.
Harris DH, Gilsenan AW, Midkiff KD, Harding AA. Navigating the registry-specific approval process for a long-term drug safety surveillance study. Presented at the NAACCR - North American Association of Central Cancer Registries; June 2013.
Midkiff KD, Harris DH, Gilsenan AW, Powell GL. Variations among cancer registries in accessing patients for a drug safety surveillance study. Poster presented at the NAACCR; June 2013.
Gilsenan AW, Andrews EB. Considerations and strategies for benefit-risk assessment in the real-world setting. In: Sashegyi A, Felli J, Noel R, editors. Benefit-risk assessment in pharmaceutical research and development. 1st ed. Boca Raton: United States. CRC Press; 2013. p.153-64.
Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Massica D. Seeing the big picture in long-term surveillance for rare events. Presented at the North American Association of Central Cancer Registries Annual Conference; 2013.
Stanford RH, Gilsenan AW, Lincourt W, Lankevich C, Ortega H. Status of asthma control in primary care in the US: results from the asthma control characteristics and prevalence survey study (ACCESS). Presented at the American College of Asthma Allergy and Immunology Annual Meeting; November 2008.
Lincourt W, Stanford RH, Gilsenan AW, Lankevich C, Vanderpuije A, Ortega H. Status of asthma control in pediatric practices in the US: results from the asthma control characteristics and prevalence survey study (ACCESS). Poster presented at the American College of Nurse Practitioner Meeting; October 2008.
Gilsenan AW, Ladner A, Varas-Lorenzo C, Kold Olesen T, Karup C, Andrews EB. Incidence of cardiovascular and cerebrovascular events among men with prostate cancer. Poster presented at the 24th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 9, 2008. Copenhagen, Denmark.
Andrews EB, Irish WD, Gilsenan AW, Campbell WH. Evaluation of therapeutic risk management programs. In: Hartzema AG, Tilson HH, Arnold Chan K, editors. Pharmacoepidemiology and therapeutic risk management. 1st ed. Cincinnati: United States. Harvey Whitney Books; 2008. p.637-52.
Andrews EB, Gilsenan AW, Cook SF. Therapeutic risk management interventions: feasibility and effectiveness. In: Pharmacoepidemiology and therapeutic risk management. Cincinnati: United States. Harvey Whitney Books; 2008. p.613-33.